Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions

Real-World Insights into Efficacy and Safety of Enfortumab Vedotin in Japanese Patients with Metastatic Urothelial Carcinoma: Findings, Considerations, and Future Directions

This study presents the enfortumab vedotin (EV) treatment analysis at our institution. We retrospectively analyzed patients with metastatic urothelial cancer (mUC) treated with EV between January 2021 and October 2023. EV was administered at 1.25 mg/kg on days 1, 8, and 15 in a 28-day cycle. Whole-b...

Full description

Bibliographic Details
Main Authors: Yuki Endo, Jun Akatsuka, Hayato Takeda, Hiroya Hasegawa, Masato Yanagi, Yuka Toyama, Hikaru Mikami, Mikio Shibasaki, Go Kimura, Yukihiro Kondo
Format: Article
Language:English
Published: MDPI AG 2024-01-01
Series:Current Oncology
Subjects:
metastatic urothelial carcinoma
enfortumab vedotin
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/1718-7729/31/2/56

Internet

https://www.mdpi.com/1718-7729/31/2/56

Similar Items